Category: Clinical Trial Watch
-
The Paradoxical Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression that is Reversible by MEK and PI3K inhibition
↵* Corresponding Author: F. Stephen Hodi, Medical Oncology, Dana-Farber Cancer Inst., 450 Brookline Aveneue, Boston, MA, 02215, United States stephen_hodi@dfci.harvard.edu Abstract Purpose: Selective BRAF inhibition (BRAFi) provides a paradigm shift for melanoma treatment. The duration of benefit is typically limited before resistance develops. Interest remains in combining targeted and immune therapies to overcome resistance and…
-
ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients Read more here: http://www.sacbee.com/2012/10/25/4937522/abraxane-demonstrates-significant.html#storylink=cpy
MELBOURNE, Australia, Oct. 25, 2012 — /PRNewswire/ — Specialised Therapeutics Australia Pty Ltd today announced that abstracts for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal at http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12023/abstract. The publication includes an abstract reviewing results from a phase III metastatic melanoma study with ABRAXANE® (nanoparticle albumin-bound paclitaxel).…
-
ZIOPHARM Oncology Announces Compelling Clinical Activity in Phase 1 Study of Ad-RTS IL-12 in Advanced Melanoma and Dosing of First Patient in Phase 2 Study
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that compelling clinical activity was seen in its Phase 1 study of Ad-RTS IL-12, a novel DNA-based therapeutic candidate, in advanced melanoma. Based on early activity, and determination of a biologically effective dose, the Company also…
-
Two-drug combination best for melanoma
National report — A two-drug combination for metastatic melanoma reduced the odds of progression by 60 percent, demonstrating more effectiveness than monotherapy, according to researchers. The study demonstrated that the BRAF-inhibitor dabrafenib and the MEK-inhibitor trametinib resulted in a median progression-free survival of 9.4 months compared to 5.8 months for patients who received only dabrafenib,…
-
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status
Background Melanoma is the most lethal form of skin cancer, but recent advances in molecularly targeted agents against the Ras/Raf/MAPK pathway demonstrate promise as effective therapies. Despite these advances, resistance remains an issue, as illustrated recently by the clinical experience with vemurafenib. Such acquired resistance appears to be the result of parallel pathway activation, such…
-
Dabrafenib in Patients With Val600Glu or Val600Lys BRAF-Mutant Melanoma Metastatic to the Brain (BREAK-MB): A Multicentre, Open-Label, Phase 2 Trial
Abstract Background: Brain metastases are common in patients with metastatic melanoma and median overall survival from their diagnosis is typically 17–22 weeks. We assessed dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain.Methods: We undertook a multicentre, open-label, phase 2 trial in 24 centres in six countries. We enrolled patients with…
-
IFN-gamma specifically targets melanoma stem cells and inhibits in vitro spherogenic growth
Cancer at its most fundamental level involves dysregulated and inexorable local and metastatic growth of abnormal cells, leading to patient mortality. The limited therapeutic benefit of current treatments is likely to relate to the existence of therapy-resistant, virulence-conferring cancer cell subpopulations. One of these subpopulations may coincide with Cancer Stem Cells (CSCs). CSCs are a…
-
Investigative therapy for melanoma promising
Combination of chemotherapy and immunotherapy of adoptive cell transfer with tumor infiltrating lymphocytes, followed by interleukin-2, is labor-intensive but a feasible therapy with a high response rate in treated patients.
-
Relative Roles of Targeted Therapies and Immunotherapies in Melanoma
Anti PD1. Dr. Mario Sznol is Professor of Medicine at the Yale School of Medicine and the clinical Research Program Leader of the Yale Cancer Center’s Melanoma Program. In this interview, Dr. Sznol shares unique insights into these two treatment approaches, including how they compare and how they might be combined
-
Inflammation Induces Melanoma’s ‘Invisibility’ to T-cell Immunotherapy
(ChemotherapyAdvisor) – Inflammation can trigger reversible losses of antigens from melanoma cell surfaces, cloaking tumors from T-cell detection, report authors of a study published in the journal Nature. The finding might help explain melanoma resistance and relapse after initially-effective immunotherapy, the authors reported. “Adaptive cell transfer therapies (ACTs) using cytotoxic T-cells that target melanocytic antigens…